Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in Pediatric Patients (2-<6 years) with Rare Genetic Obesity
NCT04966741Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Sep 2023
- Modality
- Peptides, Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of setmelanotide in obesity, pro-opiomelanocortin deficiency, proprotein convertase subtilisin/kexin type 1 deficiency, leptin receptor deficiency, Bardet–Biedl syndrome (BBS), sponsored by Rhythm Pharmaceuticals. Started Mar 2022; status: completed.
02
Drugs
setmelanotide
03
Conditions
obesitypro-opiomelanocortin deficiencyproprotein convertase subtilisin/kexin type 1 deficiencyleptin receptor deficiencyBardet–Biedl syndrome (BBS)
Beyond the preview
Go deeper on NCT04966741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966741.